Valuation: Royalty Pharma plc

Market Cap 26.23B 22.79B 21.16B 19.51B 36.76B 2,504B 37.42B 251B 98.08B 1,244B 98.51B 96.36B 4,183B P/E 2026 *
22.4x
P/E 2027 * 15.6x
Enterprise Value 35.39B 30.74B 28.54B 26.32B 49.58B 3,378B 50.48B 338B 132B 1,678B 133B 130B 5,642B EV / Sales 2026 *
10.2x
EV / Sales 2027 * 9.59x
Free-Float
71.97%
Yield 2026 *
1.69%
Yield 2027 * 1.78%
1 day+0.22%
1 week+0.46%
Current month+5.74%
1 month+5.74%
3 months+18.37%
6 months+42.25%
Current year+53.44%
1 week 58.45
Extreme 58.45
60.44
1 month 54.95
Extreme 54.95
60.44
Current year 38.29
Extreme 38.29
60.44
1 year 34.08
Extreme 34.0805
60.44
3 years 24.05
Extreme 24.05
60.44
5 years 24.05
Extreme 24.05
60.44
10 years 24.05
Extreme 24.05
60.44
Manager TitleAgeSince
Chief Executive Officer 62 1995-12-31
Director of Finance/CFO 44 2009-12-31
Chief Tech/Sci/R&D Officer - 2023-09-20
Director TitleAgeSince
Chairman 62 2020-03-31
Director/Board Member 68 2020-02-10
Director/Board Member 63 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Executive/Senior Manager

-9,099 0.0021%
6/30/26 Sell

Executive/Senior Manager

-130,000 0.0293%
6/30/26 Free

Director

689 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%+0.46%+59.73%+88.94% 26.23B
-3.98%-2.08%+52.78%+155.47% 1,079B
-3.81%-1.63%+52.49%+52.24% 640B
-1.73%+0.59%+36.52%+72.78% 465B
-2.29%+1.12%+36.13%+30.60% 353B
-2.28%-0.69%+33.42%+39.21% 301B
-3.15%+0.25%+10.63%+13.71% 271B
-2.12%+3.31%+1.82%-39.41% 228B
-0.62%+3.56%+27.66%+64.31% 209B
-1.86%-0.76%+13.16%+70.56% 165B
Average -2.19%+4.43%+32.43%+54.84% 373.59B
Weighted average by Cap. -2.93%+4.84%+38.31%+74.89%

Financials

2026 *2027 *
Net sales 3.47B 3.01B 2.8B 2.58B 4.86B 331B 4.95B 33.13B 12.97B 165B 13.03B 12.74B 553B 3.71B 3.22B 2.99B 2.76B 5.19B 354B 5.29B 35.39B 13.86B 176B 13.92B 13.61B 591B
Net income 1.65B 1.44B 1.33B 1.23B 2.32B 158B 2.36B 15.79B 6.18B 78.42B 6.21B 6.07B 264B 2.24B 1.94B 1.8B 1.66B 3.13B 214B 3.19B 21.36B 8.36B 106B 8.4B 8.22B 357B
Net Debt 9.15B 7.95B 7.38B 6.81B 12.83B 874B 13.06B 87.41B 34.22B 434B 34.37B 33.62B 1,460B 9.33B 8.1B 7.52B 6.94B 13.07B 890B 13.3B 89.05B 34.87B 442B 35.02B 34.25B 1,487B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Employees
100
Date Price Change Volume
26-07-30 US$59.29 +0.19% 1,074,247
26-07-29 US$59.18 -1.32% 2,599,135
26-07-28 US$59.97 +2.11% 3,139,110
26-07-27 US$58.73 -0.17% 1,524,177
26-07-24 US$58.83 -0.32% 2,114,330
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
59.18USD
Average target price
59.89USD
Spread / Average Target
+1.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RPRX Stock